SkinHealth Systems (SKIN) EBITDA (2020 - 2026)

SkinHealth Systems (SKIN) has 7 years of EBITDA data on file, last reported at -$1.8 million in Q1 2026.

• On a quarterly basis, EBITDA rose 85.02% year-over-year to -$1.8 million in Q1 2026; TTM through Mar 2026 was -$10.6 million, a 83.15% increase from a year earlier, with the FY2025 full-year figure at -$20.8 million, up 69.31% from the prior year.
• EBITDA for Q1 2026 stood at -$1.8 million, down from $162000.0 in the prior quarter.
• Over the last five years, EBITDA for SKIN reached as high as $162000.0 in Q4 2025 and fell as low as -$82.1 million in Q3 2023.
• Historically, EBITDA has averaged -$14.5 million across 5 years, with a median of -$12.0 million in 2025.
• Across the five-year window, EBITDA slumped 1786.08% in 2023 and surged 102.26% in 2025, its largest moves.
• Year by year, EBITDA stood at -$2.4 million in 2022, then slumped by 650.0% to -$18.4 million in 2023, then surged by 61.02% to -$7.2 million in 2024, then jumped by 102.26% to $162000.0 in 2025, then tumbled by 1211.73% to -$1.8 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$1.8 million in Q1 2026, $162000.0 in Q4 2025, and -$6.2 million in Q3 2025.